he number of class-action lawsuits claiming securities fraud committed by life sciences companies climbed again last year, continuing a trend in which drug and device makers remain juicy targets for investors, according to a new analysis.

A total of 88 class action securities lawsuits were filed against life sciences companies in 2017, a 31 percent rise from the 67 lawsuits filed the year before and a 225 percent increase from 27 such lawsuits filed in 2012, according to the Dechert law firm, which conducted the latest analysis.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.